Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
TrivarX Reports Strong US Veteran Trial Results Supporting Objective Depression Screening
TrivarX (ASX: TRI) has delivered positive results from a US-based clinical trial that demonstrate clinically meaningful, objective detection of current major depressive episodes in veterans using the company’s single-lead electrocardiogram technology.
Latest Stories
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
Emyria Establishes First Victorian Empax Clinic for Psychedelic-Assisted Treatments
Perth-based mental health care specialist Emyria (ASX: EMD) has secured its first Empax clinic in Victoria for the psychedelic-assisted treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.
Biome Australia Launches First Human Clinical Trial on Proprietary BMB18 Strain
Biome Australia (ASX: BIO) has submitted ethics approval and registered its first human clinical trial on proprietary probiotic strain Lactobacillus plantarum BMB18 with the Australia New Zealand Clinical Trials Registry.
Algorae Pharmaceuticals Identifies 90 New Drug-Combination Candidates from AlgoraeOS V2 Analysis
Algorae Pharmaceuticals (ASX: 1AI) has identified 90 high-quality drug-combination candidates following a preliminary review of newly delivered in silico synergy predictions generated by its upgraded AlgoraeOS v2 platform.
Artrya Secures Second US Commercial Order for Salix SaaS Platform to Manage Coronary Artery Disease
Artrya (ASX: AYA) has signed a commercial agreement with US-based Northeast Georgia Health System for the use of its Salix AI cloud platform for point-of-care assessment and management of coronary artery disease.
Algorae Pharmaceuticals Achieves Independent Validation of AlgoraeOS and Launches Enhanced v2 Platform
Algorae Pharmaceuticals (ASX: 1AI) has reported independent preclinical validation of its AlgoraeOS v1 drug-combination prediction platform following a major study at the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre.
Argenica Study Confirms Compatibility of ARG-007 Candidate with Stroke Treatment Standard-of-Care Therapies
Argenica Therapeutics (ASX: AGN) has reported positive results from a drug-to-drug interaction assessment showing its lead candidate ARG-007 does not interfere with clot-dissolving agent tenecteplase in the treatment of acute ischemic stroke.
Avecho Biotechnology Receives US and EU Patent Allowances for Proprietary CBD Soft-Gel Capsule
Avecho Biotechnology (ASX: AVE) has received patent allowances from both the US Patent and Trademark Office and the European Patent Office for its cannabidiol (CBD) TPM soft-gel capsule.
Optiscan Imaging Launches Head and Neck Cancer Study Using Invue and InForm Digital Pathology Tools
Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch the nation’s first-in-human head and neck cancer imaging study utilising the InVue and InForm digital pathology devices.
Algorae Pharmaceuticals to Partner with Dr Reddy’s for Australian Supply of Chemotherapy Medicine
Algorae Pharmaceuticals (ASX: 1AI) has signed a distribution partnership with Indian multinational Dr Reddy’s Laboratories to supply chemotherapy medicine capecitabine to the Australian market.
Proteomics International Confirms US Reimbursement Price for ProMarkerD Diabetic Kidney Disease Test
Proteomics International Laboratories (ASX: PIQ) has announced that the US Centres for Medicare & Medicaid Services has set a US$390.75 reimbursement price for its PromarkerD predictive test for diabetic kidney disease.